Evidence map›Paper›PMID 21370420›Full record

ArticlePediatric blood & cancer2011

Safety of short-term valacyclovir as an anti-sickling agent in sickle-cell anemia.

Katherine L Ender, Robert H DeBellis, Bernard F Erlanger, Genia B Billote, Gary M Brittenham

Abstract readClinical Trial, Phase I
In one paragraph

Article in Pediatric blood & cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Katherine L EnderDivision of Pediatric Hematology, Columbia University Medical Center, New York, New York, USA. ke2144@columbia.edu
Robert H DeBellis
Bernard F Erlanger
Genia B Billote
Gary M Brittenham
Columbia University Irving Medical Center · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0M
NCRR NIH HHS 1 UL1 RR024156-04NCRR NIH HHS UL1 RR024156
6 · The paper itself

Abstract

To assess safety and tolerability, we administered valacyclovir, an oral anti-viral medication that inhibits erythrocyte sickling in vitro, to 14 subjects with sickle-cell anemia for 1 week at a standard dose of 1,000 mg every 8 hr. No clinically significant adverse effects occurred. In 11 subjects in steady state, the mean hemoglobin concentration was almost constant while the absolute reticulocyte count decreased in eight (P = 0.1) and the overall mean fell slightly although not significantly (10%, P = 0.2). These results suggest that valacyclovir is safe and well tolerated in patients with sickle-cell anemia and that a longer duration of therapy merits investigation.

Indexed as

AcyclovirAdolescentAdultAnemia, Sickle CellAntisickling AgentsAntiviral AgentsErythrocytes, AbnormalFemaleHemoglobinsHumansMaleMaximum Tolerated DoseProdrugsProspective StudiesSafetySurvival RateAcyclovirAntisickling AgentsAntiviral AgentsHemoglobinsProdrugsValacyclovirValine

Identifiers

PMID21370420
PMCPMC3138867
OpenAlexW2065136762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.